RU2001118855A - Analogues glp-1 - Google Patents

Analogues glp-1

Info

Publication number
RU2001118855A
RU2001118855A RU2001118855/04A RU2001118855A RU2001118855A RU 2001118855 A RU2001118855 A RU 2001118855A RU 2001118855/04 A RU2001118855/04 A RU 2001118855/04A RU 2001118855 A RU2001118855 A RU 2001118855A RU 2001118855 A RU2001118855 A RU 2001118855A
Authority
RU
Russia
Prior art keywords
aib
hglp
arg
lys
ala
Prior art date
Application number
RU2001118855/04A
Other languages
Russian (ru)
Other versions
RU2214418C2 (en
Inventor
Женг Ксин Донг
Original Assignee
Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик Сас
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US11125598P priority Critical
Priority to US20660198A priority
Priority to US60/111,255 priority
Priority to US09/206,601 priority
Application filed by Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик Сас filed Critical Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик Сас
Publication of RU2001118855A publication Critical patent/RU2001118855A/en
Application granted granted Critical
Publication of RU2214418C2 publication Critical patent/RU2214418C2/en

Links

Claims (18)

1. The compound of formula (I) (R 2 R 3 ) -A 7 -A 8 -A 9 -A l0 -A 11 -A 12 -A l3 -A 14 -A 15 -A 16 -A 17 -A 18 - A 19 -A 20 -A 21 -A 22 -A 23 -A 24 -A 25 -A 26 -A 27 -A 28 -A 29 -A 30 -A 31 -A 32 -A 33 -A 34 -A 35 -A 36 -A 37 -A 38 -A 39 - R 1 , (I)
where A 7 represents L-His, Ura, Paa, Pta, Amp, Tma-His,
desamino-His, or deleted;
A 8 is —Ala, D-Ala, Aib, Ace, N-Me-Ala, N-Me-D-Ala or N-Me-Gly;
A 9 represents Glu, N-Me-Glu, N-Me-Asp or Asp;
A 10 represents Gly, Acc, β-Ala or Aib;
A 11 represents Thr or Ser;
A 12 is Phe, Acc, Aic, Aib, 3-Pal, 4-Pal, β-Nal, Cha, Trp or X 1 -Phe;
A 13 represents Thr or Ser;
A 14 represents Ser or Aib;
A 15 represents Asp or Glu;
A 16 represents Val, Acc, Aib, Leu, Ile, Tle, Nle, Abu, Ala or Cha;
A 17 represents Ser or Thr;
A 18 is Ser or Thr;
And 19 represents Tyr, Cha, Phe, 3-Pal, 4-Pal, Acc, β-Nal or X 1 -Phe;
And 20 represents Leu, Acc, Aib, Nle, Ile, Cha, Tle, Val, Phe or X 1 -Phe;
A 21 represents Glu or Asp;
A 22 is Gly, Acc, β-A1a, Glu or Aib;
A 23 represents Gln, Asp, Asn or Glu;
A 24 represents Ala, Aib, Val, Abu, Tle or Acc;
A 25 represents Ala, Aib, Val, Abu, Tle, Acc, Lys, Arg, hArg, Orn, HN-CH ((CH 2 ) n -N (R 10 R 11 )) - C (O) or HN- CH ((CH 2 ) e -X 3 ) -C (O);
And 26 represents Lys, Arg, hArg, Orn, HN-CH ((CH 2 ) n -N (R 10 R 11 )) - C (O) or HN-CH ((CH 2 ) e-X 3 ) - C (O);
A 27 represents Glu, Asp, Leu, Aib or Lys;
A 28 is Phe, Pal, β-Nal, X 1 -Phe, Aic, Acc, Aib, Cha or Trp;
A 29 represents Ile, Acc, Aib, Leu, Nle, Cha, Tle, Val, Abu, Ala or Phe;
A 30 is Ala, Aib or Acc;
A 31 is Trp, β-Nal, 3-Pal, 4-Pal, Phe, Acc, Aib or Cha;
A 32 is Leu, Acc, Aib, Nle, Ile, Cha, Tle, Phe, X 1 -Phe or Ala;
A 33 is Val, Acc, Aib, Leu, Ile, Tle, Nle, Cha, Ala, Phe, Abu, Lys or X 1 -Phe;
A 34 represents Lys, Arg, hArg, Orn, HN-CH ((CH 2 ) n -N (R 10 R 11 )) - C (O) or HN-CH ((CH 2 ) e -X 3 ) - C (O);
A 35 is Gly, β-Ala, D-Ala, Gaba, Ava, HN- (CH 2 ) m -C (O), Aib, Acc or D-amino acid;
A 36 is L- or D-Arg, D- or L-Lys, D- or L-hArg, D- or L-Orn, HN-CH ((CH 2 ) n -N (R 10 R 11 )) —C (O), HN — CH ((CH 2 ) e —X 3 ) —C (O), or deleted;
A 37 is Gly, β-Ala, Gaba, Ava, Aib, Ace, Ado, Arg, Asp, Aun, Aec, HN- (CH 2 ) m -C (O), HN-CH ((CH 2 ) n -N (R 10 R 11 ) -C (O), D-amino acid, or deleted;
A 38 is D- or L-Lys, D- or L-Arg, D- or L-hArg, D- or L-Orn, HN-CH ((CH 2 ) n -N (R 10 R 11 )) —C (O), HN — CH ((CH 2 ) e —X 3 ) —C (O) Ava, Ado, Aec, or deleted;
A 39 is D- or L-Lys, D- or L-Arg, HN-CH ((CH 2 ) n -N (R 10 R 11 )) - C (O), Ava, Ado, or Aec;
X 1 in each case is independently selected from the group consisting of (C 1 -C 6 ) alkyl, OH and halogen;
R 1 represents OH, NH 2 , (C 1 -C 30 ) alkoxy, or NH-X 2 -CH 2 -Z 0 , where X 2 represents a (C 1 -C 12 ) hydrocarbon fragment, and Z 0 represents H, OH, CO 2 H or CONH 2 ;
Figure 00000001
X 3 represents
Figure 00000002
or —C (O) —NHR 12 ,
where X 4 represents, in each case independently, —C (O) -, —NH — C (O) -, or —CH 2 -;
f is, in each case, independently, an integer from 1 to 29 inclusive;
each of R 2 and R 3 is independently selected from the group consisting of H, (C 1 -C 30 ) alkyl, (C 2 -C 30 ) alkenyl, phenyl (C 1 -C 30 ) alkyl, naphthyl (C 1 -C 30 ) alkyl, hydroxy (C 1 -C 30 ) alkyl, hydroxy (C 2 -C 30 ) alkenyl, hydroxyphenyl (C 1 -C 30 ) alkyl, and hydroxy-naphthyl (C 1 -C 30 ) alkyl; or one of R 2 and R 3 represents
Figure 00000003
(C 1 -C 30 ) acyl, (C 1 -C 30 ) alkylsulfonyl, C (O) X 5 ,
Figure 00000004
or
Figure 00000005
where Y represents H, OH or NH 2 ;
r is 0-4;
q is 0-4;
X 5 represents (C 1 -C 30 ) alkyl, (C 2 -C 30 ) alkenyl, phenyl (C 1 -C 30 ) alkyl, naphthyl (C 1 -C 30 ) alkyl, hydroxy (C 1 -C 30 ) alkyl, hydroxy (C 2 -C 30 ) alkenyl, hydroxyphenyl (C 1 -C 30 ) alkyl or hydroxy-naphthyl (C 1 -C 30 ) alkyl;
e is, in each case, independently, an integer from 1 to 4 inclusive;
m is, in each case, independently, an integer from 5 to 24 inclusive;
n represents, in each case, independently, an integer from 1 to 5 inclusive;
each of R 10 and R 11 is, in each case, independently H, (C 1 -C 30 ) alkyl, (C 1 -C 30 ) acyl, (C 1 -C 30 ) alkylsulfonyl, -C ((NH) (NH 2 )) or
Figure 00000006
R 12 and R 13 each represents, in each case independently, (C 1 -C 30 ) alkyl;
provided that if A 7 is Ura, Paa or Pta, then R 2 and R 3 are removed; if R 10 is (C 1 -C 30 ) acyl, (C 1 -C 30 ) alkylsulfonyl, —C ((NH) (NH 2 )), or
Figure 00000007
then R 11 represents H or (C 1 -C 30 ) alkyl; (i) at least one amino acid of the compound of formula (I) is different from the corresponding amino acid of the native sequence hGLP-1 (7-36, -37 or -38) NH 2 or hGLP-1 (7-36, -37 or -38) HE; (ii) the compound of formula (I) is not an analogue of hGLP-1 (7-36, -37 or -38) NH 2 or hGLP-1 (7-36, -37 or -38) OH, where the substitution is made in a single position on Ala; (iii) the compound of formula (I) is not (Arg 26.34 , Lys 38 ) hGLP-1 (7-38) -E, (Lys 26 (Nε-alkanoyl)) hGLP-1 (7-36, -37 or -38) -E, (Lys 34 (Nε-alkanoyl)) hGLP-1 (7-36, -37 or -38) -E, (Lys 26.34- bis (Nε-alkanoyl)) hGLP-1 (7 -36, -37 or -38) -E, (Arg 26 , Lys 34 (Nε-alkanoyl)) hGLP-1 (8-36, -37 or -38) -E, (Arg 26.34 , Lys 36 ( Nε-alkanoyl)) hGLP-1 (7-36, -37 or -38) -E or (Arg 26.34 , Lys 38 (Nε-alkanoyl)) hGLP-1 (7-38) -E, where E represents is —OH or —NH 2 ; (iv) the compound of formula (I) is not Z 1- hGLP-1 (7-36, -37 or -38) -OH, Z 1 -hGLP-1 (7-36, -37 or -38) -NH 2 where Z 1 is selected from the group consisting of: (e) (Arg 26 ), (Arg 34 ), (Arg 26.34 ), (Lys 36 ), (Arg 26 , Lys 36 ), (Arg 34 , Lys 36 ), (D-Lys 36 ), (Arg 36 ), (D-Arg 36 ), (Arg 26.34 , Lys 36 ) or (Arg 26.36 , Lys 34 ); (f) (Asp 21 ); (g) at least one of (Aib 8 ), (D-Ala 8 ) and (Asp 9 ); and (h) (Tyr 7 ), (N-acyl-His 7 ), (N-alkyl-His 7 ), (N-acyl-D-His 7 ) or (N-alkyl-D-His 7 ); (v) the compound of formula (I) is not a combination of any two substitutions listed in groups (a) to (d); and (vi) the compound of formula (I) is not (N-Me-Ala 8 ) hGLP-1 (8-36, or -37), (Glu 15 ) hGLP-1 (7-36, or -37), ( Asp 21 ) hGLP-1 (7-36, or -37) or (Phe 31 ) hGLP-1 (7-36, or -37), or a pharmaceutically acceptable salt thereof.
2. The compound according to claim 1, where A 11 represents Thr; A 13 is Thr; A 15 represents Asp; A 17 represents Ser; A 18 is Ser; A 21 represents Glu; A 23 represents Gln or Glu; A 27 represents Glu; and A 31 represents Trp; or a pharmaceutically acceptable salt thereof.
3. The compound according to claim 2, where A 9 represents Glu, N-Me-Glu or N-Me-Asp; A 12 represents Phe, Acc or Aic; A 16 represents Val, Acc or Aib; A 19 is Tyr; And 20 represents Leu, Acc or Cha; A 24 represents Ala, Aib or Acc; A 25 represents Ala, Aib, Acc, Lys, Arg, hArg, Orn, HN-CH ((CH 2 ) n -N (R 10 R 11 )) - C (O) or HN-CH ((CH 2 ) e- X 3 ) -C (O); A 28 represents Phe; A 29 represents Ile or Acc; A 30 is Ala or Aib; A 32 represents Leu, Acc or Cha; and A 33 represents Val or Acc; or a pharmaceutically acceptable salt thereof.
4. The compound according to claim 3, where A 8 represents Ala, D-Ala, Aib, A6c, A5c, N-Me-Ala, N-Me-D-Ala or N-Me-Gly; A 10 represents Gly; A 12 is Phe, A6c or A5c; A 16 represents Val, A6c or A5c; A 20 is Leu, A6c, A5c or Cha; A 22 represents Gly, β-Ala or Aib; A 24 represents Ala or Aib; A 29 represents Ile, A6c or A5c; A 32 is Leu, A6c, A5c or Cha; A 33 is Val, A6c or A5c; A 35 is Aib, β-Ala, Ado, A6c, A5c or Gly; and A 37 is Gly, Aib, β-Ala, Ado, D-Ala or is deleted; or a pharmaceutically acceptable salt thereof.
5. The compound according to claim 4 or a pharmaceutically acceptable salt thereof, wherein X 4 in each case is —C (O) -; e in each case independently represents 1 or 2; and R 1 represents OH or NH 2 .
6. The compound according to claim 5 or a pharmaceutically acceptable salt thereof, wherein R 2 is H and R 3 is (C 1 -C 30 ) alkyl, (C 2 -C 30 ) alkenyl, (C 1 -C 30 ) acyl , (C 1 -C 30 ) alkylsulfonyl,
Figure 00000008
Figure 00000009
or
Figure 00000010
7. The compound according to claim 5 or its pharmaceutically acceptable salt, where R 10 represents (C 1 -C 30 ) acyl, (C 1 -C 30 ) alkylsulfonyl or
Figure 00000011
and R 11 represents N.
8. The compound according to claim 7 or its pharmaceutically acceptable salt, where R 10 represents (C 4 -C 20 ) acyl, (C 4 -C 20 ) alkylsulfonyl or
Figure 00000012
9. The compound of claim 1, wherein said compound is
(Aib 8.35 ) hGLP-1 (7-36) NH 2 ,
((Nα-HEPES-His) 7 , Aib 8.35 ) hGLP-1 (7-36) NH 2 ,
((Nα-HEPA-His) 7 , Aib 8.35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26.34 , Lys 36 (Nε-tetradecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26 , Lys 34 (Nε-tetradecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35.37 , Arg 26.34 , Lys 38 (Nε-tetradecanoyl)) hGLP-1 (7-38) NH 2 ,
(Aib 8.35 , Arg 26.34 , Lys 36 (Nε-decanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26.34 , Lys 36 (Nε-dodecansulfonyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26.34 , Lys36 (Nε- (2- (4-tetradecyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26.34 , Asp 36 (1- (4-tetradecyl-piperazine)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26.34 , Lys 36 (1-tetradecylamino)) hGLP-1 (7-36) NH 2 , (Aib 8.35 , Arg 26.34 , Lys36 (Nε-tetradecanoyl), β- Ala 37 ) hGLP-1 (7-37) -OH, or
(Aib 8.35 , Arg 26.34 , Lys 36 (Nε-tetradecanoyl)) hGLP-1 (7-36) -OH,
 or a pharmaceutically acceptable salt thereof.
10. The compound of claim 9, wherein said compound is
(Aib 8.35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26 , Lys 34 (Nε-tetradecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35.37 , Arg 26.34 , Lys 38 ( Nε-tetradecanoyl)) hGLP-1 (7-38) NH 2 ,
(Aib 8.35 , Arg 26.34 , Lys 36 (Nε-decanoyl)) hGLP-1 (7-36) NH 2 , or
(Aib 8.35 , Arg 26.34 , Lys 36 (Nε-tetradecanoyl), β-Ala 37 ) hGLP-1 (7-37) -OH,
or a pharmaceutically acceptable salt thereof.
11. A pharmaceutical composition comprising an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
12. A method of inducing an agonistic effect on a GLP-1 receptor in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.
13. A method of treating a disease selected from the group consisting of type I diabetes, type II diabetes, obesity, glucagonomas, secretory disorders of the respiratory tract, metabolic disorders, arthritis, osteoporosis, diseases of the central nervous system, restenosis and neurodegenerative diseases in a subject in need thereof which comprises administering to said subject an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.
14. The method of claim 13, wherein said disease is type I diabetes or type II diabetes.
15. The method according to claim 1, where the said compound is a
(Aib 35 ) hGLP-1 (7-36) NH 2 ,
(β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
((Nα-Me-His) 7 , Aib 8.35 ) hGLP-1 (7-36) NH 2 ,
((Nα-Me-His) 7 , Aib 8 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
((Nα-Me-His) 7 , Aib 8.35 , Arg 26.34 ) hGLP-1 (7-36) NH 2 ,
((Nα-Me-His) 7 , Aib 8 , Arg 26.34 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , A6c 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , A5c 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , D-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , A6c 32 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , A5c 32 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Glu 23 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.24.35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.30.30 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.25.35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , A6c 16.20 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , A6c 16.29.29.32 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , A6c 20.32 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , A6c 20 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Lys 25 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.24.35 , A6c 20 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , A6c 29.32 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.24.35 , A6c 29.32 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , A6c 12 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Cha 20 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , A6c 33 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , A6c 20.32 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , A6c 16.20 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , β-Ala 22 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.22.35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Glu 23 , A6c 32 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.24.35 , Glu 23 , A6c 32 ) hGLP-1 (7-36) NH 2 ,
(Aib 8,24,25,35 , Glu 23 , A6c 32 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.24 , .25.35 , A6c 16.20.32 , Glu 23 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , A6c 32 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , A5c 32 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Glu 23 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.24 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.30 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.25 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , A6c 16.20 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , A6c 16,29,32 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , A6c 20.32 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , A6c 20 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Lys 25 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.24 , A6c 20 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , A6c 29.32 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.24 , A6c 29.32 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , A6c 12 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Cha 20 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , A6c 33 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , A6c 20.32 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.22 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Glu 23 , A6c 32 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.24 , Glu 23 , A6c 32 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.24 , Glu 23 , A6c 32 , Lys 34 (N ε- octanoyl), β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.24.25 , Glu 23 , A6c 32 , β- Ala35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.24.25 , A6c 16.20.32 , Glu 23 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , D-Arg 36 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , D-Lys 36 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , β-Ala 35 , D-Arg 36 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , β-Ala 35 , D-Lys 36 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26.34 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Arg 26.34 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 25.26.34 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 25.26.34 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Arg 26.34 , β-Ala 35 , Lys 35 (Nε-tetradecanoyl)) hGLP-1 (7-36) OH,
(Aib 8.35 , Arg 26.34 , Lys 36 (N ε -tetradecanoyl)) hGLP-1 (7-37) OH,
(Aib 8.35.37 , Arg 26.34 , Lys 36 (N ε -tetradecanoyl)) hGLP-1 (7-37) OH,
(Aib 8.35 , Arg 26.34 , Lys 36 (N ε -tetradecanoyl), D-Ala 37 ) hGLP-1 (7-37) OH,
(Aib 8.35.37 , Arg 26.34 , Lys 38 (N ε -tetradecanoyl)) hGLP-1 (7-38) OH,
(Aib 8.35 , Arg 26.34 , β-Ala 37 , Lys 38 (N ε -tetradecanoyl)) hGLP-1 (7-38) OH,
(Aib 8.35 , Arg 26.34 , Lys 38 (N ε -tetradecanoyl)) hGLP-1 (7-38) OH,
(Aib 8 , Arg 26.34 , Lys 36 (N ε -tetradecanoyl), β-Ala 37 ) hGLP-1 (7-37) OH,
(Aib 8.37 , Arg 26.34 , Lys 36 (N ε -tetradecanoyl)) hGLP-1 (7-37) OH,
(Aib 8.35 , Arg 26.34 , Ado 37 ) hGLP-1 (7-37) OH,
(Aib 8.35 , Arg 26.34 , Ado 37 ) hGLP-1 (7-37) NH 2 ,
(Aib 8 , Arg 26.34 , Lys 36 (N ε -tetradecanoyl), D-Ala 37 ) hGLP-1 (7-37) OH,
(Aib 8.37 , Arg 26.34 , Lys 38 (N ε -tetradecanoyl)) hGLP-1 (7-38) OH,
(Aib 8 , Arg 26.34 , β-Ala 37 , Lys 38 (N ε -tetradecanoyl)) hGLP-1 (7-38) OH,
(Aib 8.35 , Lys 26 (N ε- octanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Lys 26 (N ε -tetradecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Lys 26 (N ε ε- hexadecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Lys 26 (N ε- octanoyl), β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Lys 26 (N ε -tetradecanoyl), β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Lys 26 (N ε- hexadecanoyl), β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Lys 26 (N ε- octanoyl), Arg 34 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Lys 26 (N ε -tetradecanoyl), Arg 34 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Lys 26 (N ε ε- hexadecanoyl), Arg 34 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Lys 26 (N ε- decanoyl), Arg 34 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Lys 25 , Lys 26 (N ε- octanoyl), Arg 34 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Lys 25 , Lys 26 (N ε -tetradecanoyl), Arg 34 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Lys 25 , Lys 26 (N ε- hexadecanoyl), Arg 34 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 25.34 , Lys 26 (N ε- octanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 25.34 , Lys 26 (N ε -tetradecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 25.34 , Lys 26 (N ε ε- hexadecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 25.34 , Lys 26 (N ε -decanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Lys 26 (N ε- octanoyl), Arg 34 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Lys 26 (N ε -tetradecanoyl), Arg 34 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Lys 26 (N ε- hexadecanoyl), Arg 34 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Lys 26 (N ε- decanoyl), Arg 34 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Lys 34 (N ε- octanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Lys 34 (N ε -tetradecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Lys 34 (N ε ε- hexadecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26 , Lys 34 (N ε- octanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26 , Lys 34 (N ε ε- hexadecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26 , Lys 34 (N ε -decanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 25.26 , Lys 34 (N ε- octanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 25.26 , Lys 34 (N ε -tetradecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 25.26 , Lys 34 (N ε -hexadecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 25.26 , Lys 34 (N ε -decanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Lys 25 , Arg 26 , Lys 34 (N ε- octanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Lys 25 , Arg 26 , Lys 34 (N ε -tetradecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Lys 25 , Arg 26 , Lys 34 (N ε ε- hexadecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Lys 36 (N ε- octanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Lys 36 (N ε -tetradecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Lys 36 (N ε ε- hexadecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26 , Lys 36 (N ε- octanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26 , Lys 36 (N ε -tetradecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26 , Lys 36 (N ε ε- hexadecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26.34 , Lys 36 (N ε- octanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26.34 , Lys 36 (N ε- hexadecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26.34 , Lys 38 (N ε- octanoyl)) hGLP-1 (7-38) NH 2 ,
(Aib 8.35 , Arg 26.34 , Lys 38 (N ε -decanoyl)) hGLP-1 (7-38) NH 2 ,
(Aib 8.35 , Arg 26.34 , Lys 38 (N ε -tetradecanoyl)) hGLP-1 (7-38) NH 2 ,
(Aib 8.35 , Arg 26.34 , Lys 38 (N ε- hexadecanoyl)) hGLP-1 (7-38) NH 2 ,
(Aib 8.35.37 , Arg 25.26.34 , Lys 38 (N ε- octanoyl)) hGLP-1 (7-38) NH 2 ,
(Aib 8.35.37 , Arg 25.26.34 , Lys 38 (N ε- decanoyl)) hGLP-1 (7-38) NH 2 ,
(Aib 8.35.37 , Arg 25.26.34 , Lys 38 (N ε -tetradecanoyl)) hGLP-1 (7-38) NH 2 ,
(Aib 8.35.37 , Arg 25.26.34 , Lys 38 (N ε -hexadecanoyl)) hGLP-1 (7-38) NH 2 ,
(Aib 8.35.37 , Arg 26.34 , Lys 38 (N ε- octanoyl)) hGLP-1 (7-38) NH 2 ,
(Aib 8.35.37 , Arg 26.34 , Lys 38 (N ε -decanoyl)) hGLP-1 (7-38) NH 2 ,
(Aib 8.35.37 , Arg 26.34 , Lys 38 (N ε ε- hexadecanoyl)) hGLP-1 (7-38) NH 2 ,
(Aib 8.35.37 , Arg 25.26.34 , Lys 38 (N ε- octanoyl)) hGLP-1 (7-38) NH 2 ,
(Aib 8.35.37 , Arg 25.26.34 , Lys 38 (N ε- decanoyl)) hGLP-1 (7-38) NH 2 ,
(Aib 8.35.37 , Arg 25.26.34 , Lys 38 (N ε -tetradecanoyl)) hGLP-1 (7-38) NH 2 ,
(Aib 8.35.37 , Arg 25.26.34 , Lys 38 (N ε -hexadecanoyl)) hGLP-1 (7-38) NH 2 ,
(Aib 8.35 , Lys 25 , Arg 26.34 , Lys 36 (N ε- octanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Lys 25 , Arg 26.34 , Lys 36 (N ε -tetradecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Lys 25 , Arg 26.34 , Lys 36 (N ε ε- hexadecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 25.26.34 , Lys 36 (N ε- octanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 25.26.34 , Lys 36 (N ε -tetradecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 25.26.34 , Lys 36 (N ε ε- hexadecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 25.26.34 , Lys 36 (N ε -decanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Lys 34 (N ε- octanoyl), β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , A6c 32 , Lys 34 (N ε -tetradecanoyl), β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Lys 34 (N ε- hexadecanoyl), β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Lys 34 (N ε- octanoyl), β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Glu 23 , Lys 34 (N ε- octanoyl), β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Glu 23 , A6c 32 , Lys 34 (N ε- octanoyl), β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Arg 26 , Lys 34 (N ε- octanoyl), β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Arg 26 , Lys 34 (N ε -tetradecanoyl), β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Arg 26 , Lys 34 (N ε- hexadecanoyl), β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Arg 26 , Lys 34 (N ε- decanoyl), β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Arg 25.26 , Lys 34 (N ε- octanoyl), β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Arg 25.26 , Lys 34 (N ε -tetradecanoyl), β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Arg 25.26 , Lys 34 (N ε -hexadecanoyl), β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Arg 25.26 , Lys 34 (N ε- decanoyl), β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Lys 25 , Arg 26 , Lys 34 (N ε- octanoyl), β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Lys 25 , Arg 26 , Lys 34 (N ε -tetradecanoyl), β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Lys 25 , Arg 26 , Lys 34 (N ε ε- hexadecanoyl), β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , β-Ala 35 , Lys 36 (N ε- octanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8 , β-Ala 35 , Lys 36 (N ε -tetradecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8 , β-Ala 35 , Lys 36 (N ε -hexadecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Arg 26 , β-Ala 35 , Lys 36 (N ε- octanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Arg 26 , β-Ala 35 , Lys 36 (N ε -tetradecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Arg 26 , β-Ala 35 , Lys 36 (N ε ε- hexadecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Arg 26.34 , β-Ala 35 , Lys 36 (N ε ε- octanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Arg 26.34 , β-Ala 35 , Lys 36 (N ε -tetradecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Arg 26.34 , β-Ala 35 , Lys 36 (N ε ε- hexadecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Arg 26.34 , β-Ala 35 , Lys 36 (N ε- decanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Lys 25 , Arg 26.34 , β-Ala 35 , Lys 36 (N ε- octanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Lys 25 , Arg 26.34 , Lys 36 (N ε -tetradecanoyl) β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Lys 25 , Arg 26.34 , β-Ala 35 , Lys 36 (N ε ε- hexadecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Arg 25.26.34 , β-Ala 35 , Lys 36 (N ε- octanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Arg 25.26.34 , β-Ala 35 , Lys 36 (N ε -tetradecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Arg 25.26.34 , β-Ala 35 , Lys 36 (N ε ε- hexadecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Arg 25.26.34 , β-Ala 35 , Lys 36 (N ε- decanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Lys 26 (N ε- octanoyl), A6c 32 , Arg 34 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Lys 26 (N ε -tetradecanoyl), A6c 32 , Arg 34 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Lys 26 (N ε- hexadecanoyl), A6c 32 , Arg 34 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , A6c 32 , Lys 34 (N ε- octanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , A6c 32 , Lys 34 (N ε -tetradecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , A6c 32 , Lys 34 (N ε- hexadecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26 , A6c 32 , Lys 34 (N ε- octanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26 , A6c 32 , Lys 34 (N ε -tetradecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , A6c 32 , Lys 36 (N ε- octanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , A6c 32 , Lys 36 (N ε -tetradecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , A6c 32 , Lys 36 (N ε ε- hexadecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26 , A6c 32 , Lys 36 (N ε- octanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26 , A6c 32 , Lys 36 (N ε -tetradecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26 , A6c 32 , Lys 36 (N ε ε- hexadecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26.34 , A6c 32 , Lys 36 (N ε- octanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26.34 , A6c 32 , Lys 36 (N ε- decanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26.34 , A6c 32 , Lys 36 (N ε -tetradecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26.34 , A6c 32 , Lys 36 (N ε ε- hexadecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.24.35 , Lys 26 (N ε- octanoyl), Arg 34 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.24.35 , Lys 26 (N ε -tetradecanoyl), Arg 34 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.24.35 , Lys 26 (N ε- hexadecanoyl), Arg 34 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.24.35 , Arg 26 , Lys 34 (N ε- octanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.24.35 , Arg 26 , Lys 34 (N ε -tetradecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.24.35 , Arg 26 , Lys 34 (N ε- hexadecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.24.35 , Arg 26.34 , Lys 36 (N ε- octanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.24.35 , Arg 26.34 , Lys 36 (N ε -tetradecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.24.35 , Arg 26.34 , Lys 36 (N ε ε- hexadecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.24.35 , Glu 23 , A6c 32 , Lys 34 (N ε- octanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Glu 23 , Lys 26 (N ε- octanoyl), Arg 34 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Glu 23 , Lys 26 (N ε -tetradecanoyl), Arg 34 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Glu 23 , Lys 26 (N ε- hexadecanoyl), Arg 34 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Glu 23 , Lys 34 (N ε- octanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Glu 23 , A6c 32 , Lys 34 (N ε- octanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Glu 23 , Arg 26 , Lys 34 (N ε- octanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Glu 23 , Arg 26 , Lys 34 (N ε -tetradecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Glu 23 , Arg 26 , Lys 34 (N ε ε- hexadecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Glu 23 , Lys 36 (N ε- octanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Glu 23 , Lys 36 (N ε -tetradecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Glu 23 , Lys 36 (N ε -hexadecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Glu 23 , Arg 26.34 , Lys 36 (N ε- octanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Glu 23 , Arg 26.34 , Lys 36 (N ε -tetradecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Glu 23 , Arg 26.34 , Lys 36 (N ε -hexadecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.30.30 , Lys 26 (N ε- octanoyl), Arg 34 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.30.30 , Lys 26 (N ε -tetradecanoyl), Arg 34 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.30.30 , Lys 26 (N ε- hexadecanoyl), Arg 34 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.30.30 , Arg 26 , Lys 34 (N ε- octanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.30.30 , Arg 26 , Lys 34 (N ε -tetradecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.30.35 , Arg 26 , Lys 34 (N ε- hexadecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.30.35 , Arg 26.34 , Lys 36 (N ε- octanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.30.30 , Arg 26.34 , Lys 36 (N ε -tetradecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.30.35 , Arg 26.34 , Lys 36 (N ε ε- hexadecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Glu 23 , A6c 32 , Lys 36 (N ε- octanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Glu 23 , A6c 32 , Lys 36 (N ε -tetradecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Glu 23 , A6c 32 , Lys 36 (N ε ε- hexadecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Glu 23 , Arg 26.34 , A6c 32 , Lys 36 (N ε- octanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Glu 23 , Arg 26.34 , A6c 32 , Lys 36 (N ε -tetradecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Glu 23 , Arg 26.34 , A6c 32 , Lys 36 (N ε ε- hexadecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.24.35 , Glu 23 , Arg 26.34 , A6c 32 , Lys 36 (N ε- octanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.24.35 , Glu 23 , Arg 26.34 , A6c 32 , Lys 36 (N ε -tetradecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.24.35 , Glu 23 , Arg 26.34 , A6c 32 , Lys 36 (N ε- hexadecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.24.30.305 , Glu 23 , Arg 26.34 , A6c 32 , Lys 36 (N ε- octanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.24.30.305 , Glu 23 , Arg 26.34 , A6c 32 , Lys 36 (N ε -tetradecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.24.30.305 , Glu 23 , Arg 26.34 , A6c 32 , Lys 36 (N ε ε- hexadecanoyl)) hGLP-1 (7-36) NH 2 ,
((N α -HEPES-His) 7 , Aib 35 ) hGLP-1 (7-36) NH 2 ,
((N α -HEPES-His) 7 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
((N α -HEPES-His) 7 , Aib 8 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
((N α -HEPA-His) 7 , Aib 35 ) hGLP-1 (7-36) NH 2 ,
((N α -HEPA-His) 7 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
((N α -HEPA-His) 7 , Aib 8 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
((N α- tetradecanoyl-His) 7 , Aib 35 ) hGLP-1 (7-36) NH 2 ,
((N α- tetradecanoyl-His) 7 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
((N α- tetradecanoyl-His) 7 , Aib 8.35 ) hGLP-1 (7-36) NH 2 ,
((N α- tetradecanoyl-His) 7 , Aib 8 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
((N α- tetradecanoyl-His) 7 , Arg 26.34 , Aib 35 ) hGLP-1 (7-36) NH 2 ,
((N α- tetradecanoyl-His) 7 , Arg 26.34 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
((N α- tetradecanoyl-His) 7 , Aib 8.35 , Arg 26.34 ) hGLP-1 (7-36) NH 2 ,
((N α- tetradecanoyl-His) 7 , Aib 8 , Arg 26.34 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
((N α- tetradecanoyl-His) 7 , Arg 26.26.34 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
((N α- tetradecanoyl-His) 7 , Aib 8.35 , Arg 25.26.34 ) hGLP-1 (7-36) NH 2 ,
((N α- tetradecanoyl-His) 7 , Aib 8 , Arg 25.26.34 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Lys 26 (N ε- octanesulfonyl), Arg 34 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Lys 26 (N ε- dodecansulfonyl), Arg 34 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Lys 26 (N ε- hexadecane sulfonyl), Arg 34 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26 , Lys 34 (N ε- octanesulfonyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26 , Lys 34 (N ε- dodecansulfonyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26 , Lys 34 (N ε -hexadecane sulfonyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26.34 , Lys 36 (N ε- octanesulfonyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26.34 , Lys 36 (N ε- hexadecane sulfonyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Asp 26 (1- (4-decylpiperazine)), Arg 34 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Asp 26 (1- (4-dodecylpiperazine)), Arg 34 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Asp 26 (1- (4-tetradecylpiperazine)), Arg 34 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Asp 26 (1- (4-hexadecylpiperazine)), Arg 34 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26 , Asp 34 (1- (4-decylpiperazine))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26 , Asp 34 (1- (4-dodecylpiperazine))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26 , Asp 34 (1- (4-tetradecylpiperazine)) hGLP-1 (7-
36) NH 2 ,
(Aib 8.35 , Arg 26 , Asp 34 (1- (4-hexadecylpiperazine))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26.34 , Asp 36 (1- (4-decylpiperazine))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26.34 , Asp 36 (1- (4-dodecylpiperazine))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26.34 , Asp 36 (1- (4-hexadecylpiperazine))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26.34 , Asp 38 (1- (4-decylpiperazine))) hGLP-1 (7-38) NH 2 ,
(Aib 8.35 , Arg 26.34 , Asp 38 (1- (4-dodecylpiperazine))) hGLP-1 (7-38) NH 2 ,
(Aib 8.35 , Arg 26.34 , Asp 38 (1- (4-tetradecylpiperazine))) hGLP-1 (7-38) NH 2 ,
(Aib 8.35 , Arg 26.34 , Asp 38 (1- (4-hexadecylpiperazine))) hGLP-1 (7-38) NH 2 ,
(Aib 8.35.37 , Arg 26.34 , Asp 38 (1- (4-decylpiperazine))) hGLP-1 (7-38) NH 2 ,
(Aib 8.35.37 , Arg 26.34 , Asp 38 (1- (4-dodecylpiperazine))) hGLP-1 (7-38) NH 2 ,
(Aib 8.35.37 , Arg 26.34 , Asp 38 (1- (4-tetradecylpiperazine))) hGLP-1 (7-38) NH 2 ,
(Aib 8.35.37 , Arg 26.34 , Asp 38 (1- (4-hexadecylpiperazine))) hGLP-1 (7-38) NH 2 ,
(Aib 8.35 , Arg 25.34 , Asp 26 (1- (4-decylpiperazine))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 25.34 , Asp 26 (1- (4-dodecylpiperazine))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 25.34 , Asp 26 (1- (4-tetradecylpiperazine))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 25.34 , Asp 26 (1- (4-hexadecylpiperazine))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 25.26 , Asp 34 (1- (4-decylpiperazine))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 25.26 , Asp 34 (1- (4-dodecylpiperazine))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 25.26 , Asp 34 (1- (4-tetradecylpiperazine))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 25.26 , Asp 34 (1- (4-hexadecylpiperazine))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 25.26.34 , Asp 36 (1- (4-decylpiperazine))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 25.26.34 , Asp 36 (1- (4-dodecylpiperazine))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 25.26.34 , Asp 36 (1- (4-tetradecylpiperazine))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 25.26.34 , Asp 36 (1- (4-hexadecylpiperazine))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 25.26.34 , Asp 38 (1- (4-decylpiperazine))) hGLP-1 (7-38) NH 2 ,
(Aib 8.35 , Arg 25.26.34 , Asp 38 (1- (4-dodecylpiperazine))) hGLP-1 (7-38) NH 2 ,
(Aib 8.35 , Arg 25.26.34 , Asp 38 (1- (4-tetradecylpiperazine))) hGLP-1 (7-38) NH 2 ,
(Aib 8.35 , Arg 25.26.34 , Asp 38 (1- (4-hexadecylpiperazine))) hGLP-1 (7-38) NH 2 ,
(Aib 8.35.37 , Arg 25.26.34 , Asp 38 (1- (4-decylpiperazine))) hGLP-1 (7-38) NH 2
(Aib 8.35.37 , Arg 25.26.34 , Asp 38 (1- (4-dodecylpiperazine))) hGLP-1 (7-38) NH 2 ,
(Aib 8.35.37 , Arg 25.26.34 , Asp 38 (1- (4-tetradecylpiperazine))) hGLP-1 (7-38) NH 2 ,
(Aib 8.35.37 , Arg 25.26.34 , Asp 38 (1- (4-hexadecylpiperazine))) hGLP-1 (7-38) NH 2 ,
(Aib 8.35 , Arg 26.34 , Glu 36 (1-dodecylamino)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Glu 26 (1-dodecylamino), Arg 34 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 28 , Glu 34 (1-dodecylamino)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35.37 , Arg 26.34 , Glu 38 (1-dodecylamino)) hGLP-1 (7-38) NH 2 ,
(Aib 8.35 , Arg 34 , Lys 26 (N ε - (2- (4-decyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 34 , Lys 26 (N ε - (2- (4-dodecyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 34 , Lys 26 (N ε - (2- (4-tetradecyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 34 , Lys 26 (N ε - (2- (4-hexadecyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26 , Lys 34 (N ε - (2- (4-decyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26 , Lys 34 (N ε - (2- (4-dodecyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26 , Lys 34 (N ε - (2- (4-tetradecyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26 , Lys 34 (N ε - (2- (4-hexadecyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26.34 , Lys 36 (N ε - (2- (4-decyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26.34 , Lys 36 (N ε - (2- (4-dodecyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26.34 , Lys 36 (N ε - (2- (4-hexadecyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26.34 , Lys 38 (N ε - (2- (4-decyl-1-piperazine) -acetyl))) hGLP-1 (7-38) NH 2 ,
(Aib 8.35 , Arg 26.34 , Lys 38 (N ε - (2- (4-dodecyl-1-piperazine) -acetyl))) hGLP-1 (7-38) NH 2 ,
(Aib 8.35 , Arg 26.34 , Lys 38 (N ε - (2- (4-tetradecyl-1-piperazine) -acetyl))) hGLP-1 (7-38) NH 2 ,
(Aib 8.35 , Arg 26.34 , Lys 38 (N ε - (2- (4-hexadecyl-1-piperazine) -acetyl))) hGLP-1 (7-38) NH 2 ,
(Aib 8.35.37 , Arg 26.34 , Lys 38 (N ε - (2- (4-decyl-1-piperazine) -acetyl))) hGLP-1 (7-38) NH 2 ,
(Aib 8.35.37 , Arg 26.34 , Lys 38 (N ε - (2- (4-dodecyl-1-piperazine) -acetyl))) hGLP-1 (7-38) NH 2 ,
(Aib 8.35.37 , Arg 26.34 , Lys 38 (N ε - (2- (4-tetradecyl-1-piperazine) -acetyl))) hGLP-1 (7-38) NH 2 ,
(Aib 8.35.37 , Arg 26.34 , Lys 38 (N ε - (2- (4-hexadecyl-1-piperazine) -acetyl))) hGLP-1 (7-38) NH 2 ,
(Aib 8.35 , Arg 25.34 , Lys 26 (N ε - (2- (4-decyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 25.34 , Lys 26 (N ε - (2- (4-dodecyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 25.34 , Lys 26 (N ε - (2- (4-tetradecyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 25.34 , Lys 26 (N ε - (2- (4-hexadecyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 25.26 , Lys 34 (N ε - (2- (4-decyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 25.26 , Lys 34 (N ε - (2- (4-dodecyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 25.26 , Lys 34 (N ε - (2- (4-tetradecyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 25.26 , Lys 34 (N ε - (2- (4-hexadecyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 25.26.34 , Lys 36 (N ε - (2- (4-decyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 25.26.34 , Lys 36 (N ε - (2- (4-dodecyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 25.26.34 , Lys 36 (N ε - (2- (4-tetradecyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 25.26.34 , Lys 36 (N ε - (2- (4-hexadecyl-1-piperazine) -acetyl))) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 25.26.34 , Lys 38 (N ε - (2- (4-decyl-1-piperazine) -acetyl))) hGLP-1 (7-38) NH 2 ,
(Aib 8.35 , Arg 25.26.34 , Lys 38 (N ε - (2- (4-dodecyl-1-piperazine) -acetyl))) hGLP-1 (7-38) NH 2 ,
(Aib 8.35 , Arg 25.26.34 , Lys 38 (N ε - (2- (4-tetradecyl-1-piperazine) -
acetyl))) hGLP-1 (7-38) NH 2 ,
(Aib 8.35 , Arg 25.26.34 , Lys 38 (N ε - (2- (4-hexadecyl-1-piperazine) -acetyl))) hGLP-1 (7-38) NH 2 ,
(Aib 8.35.37 , Arg 25.26.34 , Lys 38 (N ε - (2- (4-decyl-1-piperazine) -acetyl))) hGLP-1 (7-38) NH 2 ,
(Aib 8.35.37 , Arg 25.26.34 , Lys 38 (N ε - (2- (4-dodecyl-1-piperazine) -acetyl))) hGLP-1 (7-38) NH 2 ,
(Aib 8.35.37 , Arg 25.26.34 , Lys 38 (N ε - (2- (4-tetradecyl-1-piperazine) -acetyl))) hGLP-1 (7-38) NH 2 ,
(Aib 8.35.37 , Arg 25.26.34 , Lys 38 (N ε - (2- (4-hexadecyl-1-piperazine) -acetyl))) hGLP-1 (7-38) NH 2 ,
(Aib 8.35 , Arg 26.34 , Lys 36 (N ε -decanoyl)) hGLP-1 (7-36) OH,
(Aib 8.35 , Lys 25 , Arg 26.34 , Lys 36 (N ε- decanoyl)) hGLP-1 (7-36) OH,
(Aib 8.35 , Arg 26.34 , Ava 37 , Ado 38 ) hGLP-1 (7-38) NH 2 ,
(Aib 8.35 , Arg 26.34 , Asp 37 , Ava 38 , Ado 39 ) hGLP-1 (7-39) NH 2 ,
(Aib 8.35 , Arg 26.34 , Aun 37 ) hGLP-1 (7-37) NH 2 ,
(Aib 8.17.35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Arg 26.34 , β-Ala 35 , D-Asp 37 , Ava 38 , Aun 39 ) hGLP-1 (7-39) NH 2 ,
(Gly 8 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Ser 8 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Glu 22.23 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Gly 8 , Aib 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Lys 18 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Leu 27 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Lys 33 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Lys 18 , Leu 27 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , D-Arg 36 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , β-Ala 35 , D-Arg 37 ) hGLP-1 (7-37) NH 2 ,
(Aib 8.27 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.27 , β-Ala 35.37 , Arg 38 ) hGLP-1 (7-38) NH 2 ,
(Aib 8.27 , β-Ala 35.37 , Arg 38.39 ) hGLP-1 (7-39) NH 2 ,
(Aib 8 , Lys 18.27 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Lys 27 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , β-Ala 35 , Arg 38 ) hGLP-1 (7-38) NH 2 ,
(Aib 8 , Arg 26.34 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , D-Arg 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , β-Ala 35 , Arg 37 ) hGLP-1 (7-37) NH 2 ,
(Aib 8 , Phe 31 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Phe 31 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Nal 31 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Nal 28.31 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26.34 , Nal 31 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26.34 , Phe 31 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Nal 19.31 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Nal 12.31 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Lys 36 (N ε- decanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 34 , Lys 26 (N ε- decanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26.34 , Lys 36 (N ε- dodecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8 , β-Ala 35 , Ser 37 (O-decanoyl)) hGLP-1 (7-37) NH 2 ,
(Aib 8.27 , β-Ala 35.37 , Arg 38 , Lys 39 (N ε- octanoyl)) hGLP-1 (7-39) NH 2 ,
(Aib 8 , Arg 26.34 , β-Ala 35 , Lys 37 (N ε ε- octanoyl)) hGLP-1 (7-37) NH 2 ,
(Aib 8 , Arg 26.34 , β-Ala 35 , Lys 37 (N ε- decanoyl)) hGLP-1 (7-37) NH 2 ,
(Aib 8 , Arg 26.34 , β-Ala 35 , Lys 37 (N ε -tetradecanoyl)) hGLP-1 (7-37) NH 2 ,
(Aib 8 , Arg 26.34 , β-Ala 35 , Lys 37 (N ε ε- dodecanoyl)) hGLP-1 (7-37) NH 2 ,
(Aib 8 , Arg 26.34 , β-Ala 35 , Lys 37 (N ε ε- dodecanoyl)) hGLP-1 (8-37) NH 2 ,
or a pharmaceutically acceptable salt thereof.
16. The compound of claim 15, wherein said compound is
(Aib 8.35 , A6c 32 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Glu 23 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.24.35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Glu 23 , A6c 32 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Glu 23 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26.34 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26.34 , Lys 36 (N ε- octanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26.34 , Lys 36 (N ε -decanoyl)) hGLP-1 (7-36) OH,
(Aib 8.35 , Lys 25 , Arg 26.34 , Lys 36 (N ε- decanoyl)) hGLP-1 (7-36) OH,
(Aib 8.35 , Arg 26.34 , β-Ala 35 , Lys 36 (N ε -Ac-decanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26.34 , Ava 37 , Ado 38 ) hGLP-1 (7-38) NH 2 ,
(Aib 8.35 , Arg 26.34 , Asp 37 , Ava 38 , Ado 39 ) hGLP-1 (7-39) NH 2 ,
(Aib 8.35 , Arg 26.34 , Aun 37 ) hGLP-1 (7-37) NH 2 ,
(Aib 8.17.35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Arg 26.34 , β-Ala 35 , D-Asp 37 , Ava 38 , Aun 39 ) hGLP-1 (7-39) NH 2 ,
(Gly 8 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Ser 8 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Glu 22.23 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Gly 8 , Aib 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Lys 18 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Leu 27 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Lys 33 , β-Ala 35) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Lys 18 , Leu 27 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , D-Arg 36 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , β-Ala 35 , D-Arg 37 ) hGLP-1 (7-37) NH 2 ,
(Aib 8.27 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.27 , β-Ala 35.37 , Arg 38 ) hGLP-1 (7-38) NH 2 ,
(Aib 8.27 , β-Ala 35.37 , Arg 38.39 ) hGLP-1 (7-39) NH 2 ,
(Aib 8 , Lys 18.27 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , Lys 27 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , β-Ala 35 , Arg 38 ) hGLP-1 (7-38) NH 2 ,
(Aib 8 , Arg 26.34 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , D-Arg 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8 , β-Ala 35 , Arg 37 ) hGLP-1 (7-37) NH 2 ,
(Aib 8 , Phe 31 , β-Ala 35 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Phe 31 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Nal 31 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Nal 28.31 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26.34 , Nal 31 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26.34 , Phe 31 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Nal 19.31 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Nal 13.31 ) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Lys 36 (N ε- decanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 34 , Lys 26 (N ε- decanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8.35 , Arg 26.34 , Lys 36 (N ε- dodecanoyl)) hGLP-1 (7-36) NH 2 ,
(Aib 8 , β-Ala 35 , Ser 37 (O-decanoyl)) hGLP-1 (7-37) NH 2 ,
(Aib 8.27 , β-Ala 35.37 , Arg 38 , Lys 39 (N ε- octanoyl)) hGLP-1 (7-39) NH 2 ,
(Aib 8 , Arg 26.34 , β-Ala 35 , Lys 37 (N ε ε- octanoyl)) hGLP-1 (7-37) NH 2 ,
(Aib 8 , Arg 26.34 , β-Ala 35 , Lys 37 (N ε- decanoyl)) hGLP-1 (7-37) NH 2 ,
(Aib 8 , Arg 26.34 , β-Ala 35 , Lys 37 (N ε -tetradecanoyl)) hGLP-1 (7-37) NH 2 ,
or a pharmaceutically acceptable salt thereof.
17. The compound according to any one of claims 1 to 10 or 15, or 16, as an active ingredient of a medicament for treating a disease.
18. The compound of claim 17, wherein the disease is selected from the group consisting of type I diabetes, type II diabetes, obesity, glucagonoma, secretory disorders of the respiratory tract, metabolic disorders, arthritis, osteoporosis, diseases of the central nervous system, restenosis and neurodegenerative diseases.
RU2001118855/04A 1998-12-07 1999-12-07 Glp-1 analogs RU2214418C2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US11125598P true 1998-12-07 1998-12-07
US20660198A true 1998-12-07 1998-12-07
US60/111,255 1998-12-07
US09/206,601 1998-12-07

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2003112447/04A Division RU2288232C9 (en) 1998-12-07 1999-12-07 Glp-1 analogs

Publications (2)

Publication Number Publication Date
RU2001118855A true RU2001118855A (en) 2003-06-27
RU2214418C2 RU2214418C2 (en) 2003-10-20

Family

ID=26808753

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2001118855/04A RU2214418C2 (en) 1998-12-07 1999-12-07 Glp-1 analogs
RU2003112447/04A RU2288232C9 (en) 1998-12-07 1999-12-07 Glp-1 analogs

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2003112447/04A RU2288232C9 (en) 1998-12-07 1999-12-07 Glp-1 analogs

Country Status (23)

Country Link
US (5) US6903186B1 (en)
EP (2) EP1137667B1 (en)
JP (5) JP3702181B2 (en)
KR (3) KR20050037004A (en)
CN (2) CN100540566C (en)
AT (1) AT282635T (en)
AU (1) AU762012B2 (en)
BR (1) BR9915961A (en)
CA (1) CA2353574C (en)
CZ (6) CZ295768B6 (en)
DE (1) DE69922043T2 (en)
ES (1) ES2230912T3 (en)
HK (1) HK1037196A1 (en)
HU (1) HU0104574A3 (en)
IL (2) IL143346D0 (en)
NO (2) NO319128B1 (en)
NZ (2) NZ511931A (en)
PL (1) PL202367B1 (en)
PT (1) PT1137667E (en)
RU (2) RU2214418C2 (en)
SG (1) SG125915A1 (en)
TW (6) TW593338B (en)
WO (1) WO2000034331A2 (en)

Families Citing this family (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU762012B2 (en) 1998-12-07 2003-06-19 Ipsen Pharma S.A.S. Analogues of GLP-1
CZ303399B6 (en) 1998-12-07 2012-08-29 Ipsen Pharma S.A.S. GLP-1 peptide analogue and pharmaceutical composition containing thereof
BR0113178A (en) * 2000-08-02 2004-04-06 Theratechnologies Inc Modified biological peptides with increased potency
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
PT1326630E (en) 2000-09-18 2008-09-02 Sanos Bioscience As Use of glp-2 peptides
AU2412402A (en) 2000-12-01 2002-06-11 Takeda Chemical Industries Ltd Method for producing preparation containing bioactive substance
US7576050B2 (en) * 2001-07-31 2009-08-18 The United States Of America As Represented By The Department Of Health And Human Services GLP-1 exendin-4 peptide analogs and uses thereof
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
WO2003033671A2 (en) * 2001-10-18 2003-04-24 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US7332819B2 (en) * 2002-01-09 2008-02-19 Micron Technology, Inc. Stacked die in die BGA package
CA2500021A1 (en) * 2002-09-25 2004-04-08 Theratechnologies Inc. Modified glp-1 peptides with increased biological potency
KR20050049525A (en) * 2002-10-11 2005-05-25 가부시키가이샤산와카가쿠켄큐쇼 Glp-1 derivatives and transmicosal absorption preparations thereof
WO2004074315A2 (en) * 2003-02-19 2004-09-02 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Analogues of glp-1
CN102134577A (en) * 2003-03-28 2011-07-27 独立行政法人农业生物资源研究所 Process for producing plant storage organ with high production of recombinant protein and novel recombinant protein
DE10314610A1 (en) 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh New diphenylazetidinone with improved physiological properties, process for its preparation, medicaments containing these compounds and its use
EP2292253A3 (en) 2003-06-03 2011-12-14 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
BRPI0410972B8 (en) 2003-06-03 2018-12-04 Novo Nordisk As method for extending the shelf life of a pharmaceutical composition, pharmaceutical composition, and method for treating hyperglycemia
US7094800B2 (en) 2003-07-25 2006-08-22 Sanofi-Aventis Deutschland Gmbh Cyanopyrrolidides, process for their preparation and their use as medicaments
US7094794B2 (en) 2003-07-28 2006-08-22 Sanofi-Aventis Deutschland Gmbh Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
DE10335092B3 (en) 2003-08-01 2005-02-03 Aventis Pharma Deutschland Gmbh Substituted benzoylureido-o-benzoylamides, process for their preparation and their use
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
ES2393335T3 (en) 2003-12-16 2012-12-20 Ipsen Pharma GLP-1 analogues
EP1694278A4 (en) * 2003-12-16 2009-08-12 Ipsen Pharma Glp-1 pharmaceutical compositions
BRPI0417717A (en) * 2003-12-18 2007-04-03 Novo Nordisk As compound, pharmaceutical composition, and use of a compound
AU2005203925A1 (en) * 2004-01-08 2005-07-21 Theratechnologies Inc. Glucagon-Like Peptide-1 analogs with long duration of action
TW200611704A (en) * 2004-07-02 2006-04-16 Squibb Bristol Myers Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
CN101010339B (en) * 2004-07-02 2011-11-09 布里斯托尔-迈尔斯斯奎布公司 Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions
JP5107713B2 (en) 2004-10-07 2012-12-26 ノヴォ ノルディスク アー/エス Delayed exendin-4 compound
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
EP1841448A2 (en) 2004-12-30 2007-10-10 Diakine Therapeutics, Inc. Pharmaceutical compositions and methods for restoring beta-cell mass and function
US8052996B2 (en) 2005-02-03 2011-11-08 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US8299025B2 (en) 2005-02-03 2012-10-30 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
EP1863521B1 (en) 2005-03-18 2014-05-07 Novo Nordisk A/S Extended glp-1 compounds
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US20070004616A1 (en) * 2005-06-30 2007-01-04 Roland Cherif-Cheikh GLP-1 pharmaceutical compositions
MX2008001468A (en) 2005-06-30 2008-04-07 Sod Conseils Rech Applic Glp-1 pharmaceutical compositions.
AU2007340369C1 (en) * 2006-12-29 2013-05-02 Ipsen Pharma S.A.S. GLP-1 pharmaceutical compositions
EP2570133B1 (en) 2005-11-07 2016-03-23 Indiana University Research and Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
WO2007124461A2 (en) 2006-04-20 2007-11-01 Amgen Inc. Glp-1 compounds
SI2035451T1 (en) * 2006-06-23 2010-06-30 Hoffmann La Roche Insulinotropic peptide synthesis
GB0612669D0 (en) * 2006-06-27 2006-08-09 Univ Leeds Biomarkers for preeclampsia
KR20090047458A (en) 2006-08-08 2009-05-12 사노피-아벤티스 Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
EP2049081B1 (en) 2006-08-09 2012-11-14 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
CN101511364B (en) 2006-09-07 2012-08-15 奈科明有限责任公司 Combination treatment for diabetes mellitus
MX2009006942A (en) * 2006-12-29 2009-11-09 Ipsen Pharma Sas Glp-1 pharmaceutical compositions.
DE102007005045B4 (en) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazine derivatives, process for their preparation and their use as medicines
EA017849B1 (en) 2007-02-15 2013-03-29 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Glucagon/glp-1 receptor co-agonists
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
JP5606314B2 (en) 2007-09-05 2014-10-15 ノボ・ノルデイスク・エー/エス Peptides derivatized with ABCD and therapeutic uses thereof
JP5476304B2 (en) 2007-09-05 2014-04-23 ノボ・ノルデイスク・エー/エス Glucagon-like peptide-1 derivatives and their pharmaceutical use
CN101842386A (en) 2007-09-05 2010-09-22 诺沃-诺迪斯克有限公司 Truncated GLP-1 derivatives and their therapeutical use
US20100256056A1 (en) * 2007-09-07 2010-10-07 Zheng Xin Dong Analogues of exendin-4 and exendin-3
EP2205624B1 (en) 2007-10-27 2016-09-07 Corden Pharma Colorado, Inc. Insulinotropic peptide synthesis using solid and solution phase combination techniques
EP2214691B1 (en) 2007-10-30 2015-09-30 Indiana University Research and Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
DE102007054497B3 (en) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh New crystalline hydrate form of dodecanedioic acid 4-((2S,3R)-3-((S)-3-(4-fluoro-phenyl)-3-hydroxy-propyl)-2-(4-methoxy-phenyl)-4-oxo-azetidin-1-yl)-benzylamide ((2S,3R,4R,5R)-pentahydroxy-hexyl)-amide useful e.g. to treat hyperlipidemia
EP2222695A2 (en) * 2007-12-11 2010-09-01 F. Hoffmann-La Roche AG Insulinotropic peptide synthesis using solid and solution phase combination techniques
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
AU2009260302B2 (en) 2008-06-17 2014-10-23 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
NZ589848A (en) * 2008-06-17 2012-11-30 Univ Indiana Res & Tech Corp Gip-based mixed agonists for treatment of metabolic disorders and obesity
WO2009158704A2 (en) 2008-06-27 2009-12-30 Duke University Therapeutic agents comprising elastin-like peptides
KR20110039348A (en) 2008-08-06 2011-04-15 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Conjugated proteins with prolonged in vivo efficacy
EP2769986A3 (en) * 2008-08-07 2014-11-26 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal
KR20110043686A (en) * 2008-08-07 2011-04-27 입센 파마 에스.에이.에스 Analogues of glucose-dependent insulinotropic polypeptide
EP2320923B1 (en) * 2008-08-07 2014-12-24 Ipsen Pharma S.A.S. Truncated analogues of glucose-dependent insulinotropic polypeptide
CA2732973A1 (en) * 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Glucose-dependent insulinotropic polypeptide analogues
TW201012829A (en) * 2008-09-22 2010-04-01 Ipsen Mfg Ireland Ltd Process for the synthesis of (Aib8,35)hGLP-1(7-36)-NH2
UA104605C2 (en) 2008-12-15 2014-02-25 Зіленд Фарма А/С Glucagon analogues
AU2008365556A1 (en) 2008-12-15 2011-07-21 Zealand Pharma A/S Glucagon analogues
WO2010070253A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
ES2502218T3 (en) 2008-12-15 2014-10-03 Zealand Pharma A/S Glucagon analogues
EP2376097A4 (en) 2008-12-19 2012-10-03 Univ Indiana Res & Tech Corp Amide based glucagon superfamily peptide prodrugs
US20100183876A1 (en) * 2008-12-23 2010-07-22 Hell Andre Process for the Preparation of a Peptide Powder Form
MX2011007736A (en) 2009-01-22 2011-09-06 Novo Nordisk Healthcare Ag Stable growth hormone compounds.
EP2216042A1 (en) 2009-02-09 2010-08-11 Ipsen Pharma S.A.S. GLP-1 analogues pharmaceutical compositions
SG175411A1 (en) * 2009-05-01 2011-12-29 Hoffmann La Roche Insulinotropic peptide synthesis using solid and solution phase combination techniques
WO2010148089A1 (en) 2009-06-16 2010-12-23 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
US9156901B2 (en) 2009-07-13 2015-10-13 Ditte Riber Acylated glucagon analogues
US8841249B2 (en) 2009-08-06 2014-09-23 Novo Nordisk A/S Growth hormones with prolonged in-vivo efficacy
DK2470552T3 (en) 2009-08-26 2014-02-17 Sanofi Sa NOVEL, CRYSTALLINE, heteroaromatic FLUORGLYCOSIDHYDRATER, MEDICINES COVERING THESE COMPOUNDS AND THEIR USE
PT2462246T (en) 2009-09-28 2017-12-11 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
WO2011048614A2 (en) 2009-10-22 2011-04-28 Cadila Healthcare Limited Short chain peptidomimetics based orally active glp-1 agonist and glucagon receptor antagonist
RU2012134974A (en) 2010-01-22 2014-02-27 Ново Нордиск Хелс Кеа Аг Stabilized growth hormone compound
RU2605627C2 (en) 2010-01-22 2016-12-27 Ново Нордиск Хелс Кеа Аг Growth hormones with prolonged efficacy in vivo
WO2011094337A1 (en) 2010-01-27 2011-08-04 Indiana University Research And Technology Corporation Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
DE102010015123A1 (en) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh New benzylamidic diphenylazetidinone compounds, useful for treating lipid disorders, hyperlipidemia, atherosclerotic manifestations or insulin resistance, and for reducing serum cholesterol levels
WO2011136361A1 (en) 2010-04-30 2011-11-03 株式会社 三和化学研究所 Peptide for improving in vivo stability of physiologically active substance or the like and physiologically active substance with improved in vivo stability
EP2582709B1 (en) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
US20110313131A1 (en) 2010-06-21 2011-12-22 Christelle Carl Reversed phase hplc purification of a glp-1 analogue
AR081975A1 (en) 2010-06-23 2012-10-31 Zealand Pharma As Analogs of glucagon
AU2011269430A1 (en) * 2010-06-24 2013-01-10 Zealand Pharma A/S Glucagon analogues
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
US8507428B2 (en) 2010-12-22 2013-08-13 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683702B1 (en) 2011-03-08 2014-12-24 Sanofi New substituted phenyl oxathiazine derivatives, method for their manufacture, medicines containing these compounds and their application
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683705B1 (en) 2011-03-08 2015-04-22 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683698B1 (en) 2011-03-08 2017-10-04 Sanofi Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
JP6184404B2 (en) 2011-06-22 2017-08-23 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション Glucagon / GLP-1 Receptor Co-Agonist
WO2012177443A2 (en) 2011-06-22 2012-12-27 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
WO2013010840A2 (en) 2011-07-18 2013-01-24 Arts Biologics A/S Long acting biologically active luteinizing hormone (lh) compound
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US10100097B2 (en) 2012-05-03 2018-10-16 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
EP2851429B1 (en) 2012-05-18 2019-07-24 Adda Biotech Inc. Protein and protein conjugate for diabetes treatment, and applications thereof
WO2014010586A1 (en) 2012-07-10 2014-01-16 武田薬品工業株式会社 Pharmaceutical preparation for injection
KR101848303B1 (en) 2012-07-10 2018-04-13 삼성전자주식회사 Method for controlling power trasnmitting of wireless power transmitter and the wireless power transmitter thereof
NZ704043A (en) 2012-07-23 2017-07-28 Zealand Pharma As Glucagon analogues
TWI608013B (en) 2012-09-17 2017-12-11 西蘭製藥公司 Glucagon analogues
IN2015DN03795A (en) 2012-10-24 2015-10-02 Inserm Inst Nat De La Santé Et De La Rech Médicale
CN104936610A (en) 2012-11-13 2015-09-23 益普生制药股份有限公司 Purification method of GLP-1 analogue
WO2014077801A1 (en) 2012-11-13 2014-05-22 Ipsen Pharma S.A.S. Purification process for preparing highly pure taspoglutide
CN103536907B (en) * 2013-07-18 2015-10-21 上海交通大学医学院附属瑞金医院 The application of Arg34Lys26-(N-EPSILON-(N-ALPHA-Palmitoyl-L-GAMMA-glutamyl))-GLP-1[7-37] in osteoporosis therapy medicine
PL3057984T3 (en) 2013-10-17 2018-12-31 Zealand Pharma A/S Acylated glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
EA035688B1 (en) 2013-11-06 2020-07-27 Зилэнд Фарма А/С Glucagon-glp-1-gip triple agonist compounds
TWI670281B (en) 2013-11-06 2019-09-01 西蘭製藥公司 Gip-glp-1 dual agonist compounds and methods
US20160318987A1 (en) * 2013-12-13 2016-11-03 Medimmune Limited Protease resistant peptides
WO2015155151A1 (en) 2014-04-07 2015-10-15 Novo Nordisk A/S Double-acylated glp-1 compounds
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MX2017005457A (en) 2014-10-29 2017-07-04 Zealand Pharma As Gip agonist compounds and methods.
WO2016151018A1 (en) 2015-03-24 2016-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of diabetes
MX2017012864A (en) 2015-04-16 2018-06-12 Zealand Pharma As Acylated glucagon analogue.
CN106554409B (en) * 2015-09-30 2020-04-07 天津药物研究院有限公司 Long-acting glucagon-like peptide-1 analogue and application thereof
TW201808989A (en) 2016-05-16 2018-03-16 美商因塔希亞治療公司 Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
US20200087373A1 (en) 2017-05-31 2020-03-19 University Of Copenhagen Long-acting gip peptide analogues
US20190309040A1 (en) 2018-04-05 2019-10-10 Sun Pharmaceutical Industries Limited Novel GLP-1 Analogues
WO2020077129A1 (en) 2018-10-11 2020-04-16 Intarcia Therapeutics, Inc. Human amylin analog polypeptides and methods of use
WO2020115049A1 (en) 2018-12-03 2020-06-11 Antag Therapeutics Aps Modified gip peptide analogues

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1539498A (en) 1925-05-26 And fifteen
AT110083T (en) 1986-05-05 1994-09-15 Gen Hospital Corp Insulinotropes hormon.
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
WO1991011457A1 (en) * 1990-01-24 1991-08-08 Buckley Douglas I Glp-1 analogs useful for diabetes treatment
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
EP0658568A1 (en) 1993-12-09 1995-06-21 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
AU2263197A (en) 1996-02-06 1997-08-28 Eli Lilly And Company Diabetes therapy
US5994500A (en) 1996-07-19 1999-11-30 1149336 Ontario Inc. Antagonists of intestinotrophic GLP-2 peptides
US6458924B2 (en) * 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
JP3149958B2 (en) * 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ GLP-1 derivative
US6191102B1 (en) * 1996-11-05 2001-02-20 Eli Lilly And Company Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity
WO1998032867A1 (en) 1997-01-24 1998-07-30 Novo Nordisk A/S Synthetic leader peptide sequences
US5981488A (en) 1997-03-31 1999-11-09 Eli Lillly And Company Glucagon-like peptide-1 analogs
AU2610599A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
FR2777283B1 (en) * 1998-04-10 2000-11-24 Adir Novel glucagon-peptide- 1 (7-37) analogue peptide compounds, process for their preparation and the pharmaceutical compositions containing the same
US6720407B1 (en) * 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
AU762012B2 (en) * 1998-12-07 2003-06-19 Ipsen Pharma S.A.S. Analogues of GLP-1
CZ303399B6 (en) * 1998-12-07 2012-08-29 Ipsen Pharma S.A.S. GLP-1 peptide analogue and pharmaceutical composition containing thereof
JP2003516322A (en) 1999-11-12 2003-05-13 ノボ ノルディスク アクティーゼルスカブ Use of a GLP-1 agonist for inhibiting beta-cell degeneration

Similar Documents

Publication Publication Date Title
DE69818295D1 (en) Einhüllungssverfahren
DE69838851D1 (en) Wirbelsäulendistraktionsimplantat
DE69837412D1 (en) Ventilpositioniersystem
DE69807852D1 (en) 2-alkylides-19-nor-vitamin d-compounds
DE69840810D1 (en) nferenzbreitbanddiensten
DE69819312D1 (en) 2-alkyl-19-nor-vitamin d-compounds
DE69832354D1 (en) Netzwerkverwaltungsrahmwerk
DE69818302D1 (en) Perfusionsverbindungsvorrichtung
DE69824183D1 (en) N-alkanoylphenylalaninderivate
DE69815345D1 (en) Rückspülluftfilteranordnung
DE69836650D1 (en) Fuseanordnung
DE69827001D1 (en) gewebedezellularization
DE19810476B4 (en) laryngomaske
DE69838306D1 (en) Sauerstoffanreichungsapparat
DE69834142D1 (en) Tintenzuführsystemadapter
DE69841917D1 (en) igarettenpapierbahnen
DE69831425D1 (en) Rauchevakuiersystem
DE69826970D1 (en) Linearreibschweissverfahren
DE69827490D1 (en) Inhalatormechanismus
DE69821822D1 (en) Niederspannungsbeleuchtungsvorrichung
DE69830858D1 (en) Schweinecircoviren
DE69828310D1 (en) Gelatinzusammensetzungen
DE69801048T2 (en) Fungicidal trifluorophenyl-triazolopyrimidine
DE69839459D1 (en) Gehrungssägeschwenklagerfestspannvorrichtung
DE69832429D1 (en) Wobbelsignalerfassungschaltung